CN1267526A - Compound Chinese medicine preparation for treating hyperosteogeny - Google Patents

Compound Chinese medicine preparation for treating hyperosteogeny Download PDF

Info

Publication number
CN1267526A
CN1267526A CN 00110131 CN00110131A CN1267526A CN 1267526 A CN1267526 A CN 1267526A CN 00110131 CN00110131 CN 00110131 CN 00110131 A CN00110131 A CN 00110131A CN 1267526 A CN1267526 A CN 1267526A
Authority
CN
China
Prior art keywords
herba
chinese medicine
radix
medicine preparation
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 00110131
Other languages
Chinese (zh)
Other versions
CN1101202C (en
Inventor
陈永贵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN 00110131 priority Critical patent/CN1101202C/en
Publication of CN1267526A publication Critical patent/CN1267526A/en
Application granted granted Critical
Publication of CN1101202C publication Critical patent/CN1101202C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The Chinese medicine is especially suitable for treating cervical vertebra disease, heel pain, Kaschin-Beck disease and traumatic arthritis and its recipe includes prepared remannia rhizome, Chinese pyrola herb, desertliving cistanche herb, Rhizoma cyperi, epimedium and other six kinds of Chinese medicinal materials. It can not only treat congestion, edema, inflammation and pain caused by hyperosteogeny, but also moisten and repair degraded bone, and this results in high cure effect.

Description

A kind of compound recipe hyperosteogeny Chinese medicine preparation
The present invention relates to a kind of Chinese medicine preparation, more particularly relate to a kind of compound recipe hyperosteogeny Chinese medicine preparation, be suitable for treating ankylosing spondylitis, cervical spondylosis, talalgia, Kaschin-Beck disease and traumatic arthritis.
Hyperosteogeny belongs to motherland's medical science arthralgia, and clinical symptoms shows as lumbago more, gonalgia, talalgia.Its cause of disease and pathogeny many by Liver and kidney be foot, essence and blood loss or chronic strain, be affected by the cold, damp and hot, caused by energy stagnation and blood stasis, cause the articular cartilage face degeneration, the subcartilaginous osseous lamella reactive hyperplasia causes the joint a series of symptom characteristics such as pain, distortion, movable function is limited to occur.At present to the treatment of hyperosteogeny adopt usually acupuncture, massage, fumigation and wash method hot compress and in, the western drug therapy, but, these therapies can only alleviate and alleviate the pain at hypertrophy position, all there is not the development that specific medicament can stop the state of an illness, and the Western medicine toxic and side effects is big, adopt operative therapy though also have, particularly those serious pain and dysfunction influence routine work and live and reach with the obvious unusual person of mechanical performance, but how not remarkable curative effect is, and the probability of accident in the art and postoperative generation complication is bigger, has brought inconvenience for the treatment work of hyperosteogeny.
The purpose of this invention is to provide a kind of hyperosteogeny Chinese medicine preparation, it can not only dredge the meridian passage, strengthening the tendons and bones, treatment hypertrophy cause local organization hyperemia, edema, inflammation, eliminate pain, and also the sclerotin of just regression obtains fully moistening of essence and blood and supports and repair, therapeutic effect is good, the cure rate height.
The object of the present invention is achieved like this, it is characterized in that its prescription and each ingredients weight parts ratio are as follows:
Radix Rehmanniae Preparata 10-30 Herba Pyrolae 5-20
Herba Cistanches 10-20 Rhizoma Drynariae 4-20
Herba Epimedii 10-15 Caulis Spatholobi 10-30
Semen Raphani 5-15 Rhizoma Corydalis 3-10
Radix Cyathulae 4.5-9 Radix Clematidis 5-10
Semen Strychni (processed) 0.3-0.6
In above-mentioned prescription, wherein Radix Rehmanniae Preparata contains retinoid material and aminoacid, the treatment that enrich blood, the kidney invigorating, benefit are smart, is used for deficiency of the liver and kindey, soreness of waist and knee joint; Herba Pyrolae can dispel the wind, dehumidifying, invigorating the liver and kidney, bone and muscle strengthening, and stronger bacteriostasis is arranged; But the Herba Cistanches reinforcing the kidney and supporting YANG, can treat the chills and pain of the waist and kness that insufficiency of kidney-YANG causes; Herba Epimedii has kidney-replenishing, wind-damp dispelling, controls the easypro disease of muscles and bones contracture; But Caulis Spatholobi Shujin, active can be treated soreness of waist and knee joint, rheumatic arthralgia; Rhizoma Corydalis contains 20 kinds of alkaloids, has the promoting blood circulation and stopping pain circulation of qi promoting, can control the many pain diseases in joint, and obvious analgesic activity is arranged, and is promoting blood circulation and stopping pain good medicine; The detoxifcation of Semen Raphani anti-inflammatory and antalgic has obvious inhibitory action to various pathogenic bacterias, virus; Radix Cyathulae can be invigorated blood circulation, blood stasis dispelling, invigorating the liver and kidney, bone and muscle strengthening, anti-inflammatory and antalgic, has treatment soreness of waist and knee joint, joint stuffiness effect; But Radix Clematidis expelling wind and removing dampness, removing obstruction in the collateral to relieve pain; Contain alkaloid, fatty oil in the Semen Strychni (processed) all there is excitation in the refreshing smart system of whole maincenter.Sclerotin is given birth to deficiency in both YIN and YANG or the cold-damp that belong to kidney more and is blocked meridians and the deficiency of kidney-QI that arrives, select for use Radix Rehmanniae Preparata, Herba Cistanches to mend essence and fill marrow in order to nourishing the blood and yin, supporing yang spermatogenesis, the Herba Epimedii kidney invigorating and YANG supporting, assistant is with Rhizoma Drynariae, Herba Pyrolae, Caulis Spatholobi, Radix Clematidis the kidney invigorating, enrich blood double blood circulation promoting and blood stasis dispelling, relaxing muscles and tendons and activating QI and blood in the collateral, wind-expelling pain-stopping.Rhizoma Corydalis is used to control limbs pain due to the coagulation of QI-blood, Semen Raphani digestion-promoting spleen-invigorating eliminate indigestion, and greasy now for preventing medicine, eliminating evil just the wound to reach the hold concurrently purpose of smelting of specimen.
Advantage of the present invention is that prescription is many, dosage light, does not have toxic action, it can not only can dredge the meridian passage, strengthening the tendons and bones, treatment hypertrophy cause local organization hyperemia, edema, inflammation, eliminate pain, and the sclerotin that can make regression obtains the foster and reparation of fully moistening of essence and blood, therapeutic effect is good, cure rate height, effective percentage reach more than 90%, relieving rate reaches 70%, cure rate reaches about 50%.
Provide specific embodiments of the invention below.
Embodiment 1
Prescription and each ingredients weight parts ratio are as follows:
Radix Rehmanniae Preparata 15 Herba Pyrolaes 10
Herba Cistanches 10 Rhizoma Drynariae 10
Herba Epimedii 10 Caulis Spatholobis 10
Semen Raphani 5 Rhizoma Corydalis 5
Radix Cyathulae 8 Radix Clematidis 7
Semen Strychni (processed) 0.5
After said components taken by weighing by weight, the closeer routinely ball production technology of raw material is made close ball.
Embodiment 2
Prescription and each ingredients weight parts ratio are as follows:
Radix Rehmanniae Preparata 20 Herba Pyrolaes 20
Herba Cistanches 20 Rhizoma Drynariae 4
Herba Epimedii 13 Caulis Spatholobis 25
Semen Raphani 10 Rhizoma Corydalis 3
Radix Cyathulae 4.5 Radix Clematidis 5
After Semen Strychni (processed) 0.4 takes by weighing said components by weight, again with raw material routinely the powder production technology make powder.Embodiment 3 prescriptions and each ingredients weight parts ratio are as follows:
Radix Rehmanniae Preparata 15 Herba Pyrolaes 5
Herba Cistanches 18 Rhizoma Drynariae 8
Herba Epimedii 15 Caulis Spatholobis 15
Semen Raphani 15 Rhizoma Corydalis 10
Radix Cyathulae 5 Radix Clematidis 9
After Semen Strychni (processed) 0.6 takes by weighing said components by weight, again with raw material routinely tablet manufacturing technology make tablet.Embodiment 4 prescriptions and each ingredients weight parts ratio are as follows:
Radix Rehmanniae Preparata 30 Herba Pyrolaes 15
Herba Cistanches 15 Rhizoma Drynariae 20
Herba Epimedii 14 Caulis Spatholobis 10
Semen Raphani 8 Rhizoma Corydalis 8
Radix Cyathulae 6 Radix Clematidis 10
After Semen Strychni (processed) 0.6 takes by weighing said components by weight, the closeer routinely ball production technology of raw material is made close ball.Embodiment 5 prescriptions and each ingredients weight parts ratio are as follows:
Radix Rehmanniae Preparata 25 Herba Pyrolaes 18
Herba Cistanches 13 Rhizoma Drynariae 15
Herba Epimedii 12 Caulis Spatholobis 30
Semen Raphani 12 Rhizoma Corydalis 9
Radix Cyathulae 7 Radix Clematidis 8
After Semen Strychni (processed) 0.5 takes by weighing said components by weight, again with raw material routinely capsule manufacture technology make capsule.Embodiment 6 prescriptions and each ingredients weight parts ratio are as follows:
Radix Rehmanniae Preparata 10 Herba Pyrolaes 12
Herba Cistanches 17 Rhizoma Drynariae 18
Herba Epimedii 11 Caulis Spatholobis 23
Semen Raphani 7 Rhizoma Corydalis 6
Radix Cyathulae 9 Radix Clematidis 6
After Semen Strychni (processed) 0.6 takes by weighing said components by weight, again with raw material routinely oral liquid process make oral liquid.

Claims (1)

1. compound recipe hyperosteogeny Chinese medicine preparation is characterized in that its prescription and each ingredients weight parts ratio are as follows:
Radix Rehmanniae Preparata 10-30 Herba Pyrolae 5-20
Herba Cistanches 10-20 Rhizoma Drynariae 4-20
Herba Epimedii 10-15 Caulis Spatholobi 10-30
Semen Raphani 5-15 Rhizoma Corydalis 3-10
Radix Cyathulae 4.5-9 Radix Clematidis 5-10
Semen Strychni (processed) 0.3-0.6
CN 00110131 2000-02-22 2000-02-22 Compound Chinese medicine preparation for treating hyperosteogeny Expired - Fee Related CN1101202C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 00110131 CN1101202C (en) 2000-02-22 2000-02-22 Compound Chinese medicine preparation for treating hyperosteogeny

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 00110131 CN1101202C (en) 2000-02-22 2000-02-22 Compound Chinese medicine preparation for treating hyperosteogeny

Publications (2)

Publication Number Publication Date
CN1267526A true CN1267526A (en) 2000-09-27
CN1101202C CN1101202C (en) 2003-02-12

Family

ID=4580146

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 00110131 Expired - Fee Related CN1101202C (en) 2000-02-22 2000-02-22 Compound Chinese medicine preparation for treating hyperosteogeny

Country Status (1)

Country Link
CN (1) CN1101202C (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053167A1 (en) * 2001-12-11 2003-07-03 Societe Des Produits Nestle S.A. Composition for promotion of bone growth and maintenance of bone health
CN103655959A (en) * 2013-11-21 2014-03-26 黄萍 Externally applied traditional Chinese medicine for treating calcaneodynia
CN104474209A (en) * 2014-12-02 2015-04-01 青岛祥翔生物医药科技有限公司 Traditional Chinese medicine for treating qi-deficiency and blood-deficiency type heel pain

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053167A1 (en) * 2001-12-11 2003-07-03 Societe Des Produits Nestle S.A. Composition for promotion of bone growth and maintenance of bone health
EP1325681A1 (en) * 2001-12-11 2003-07-09 Société des Produits Nestlé S.A. Composition for promotion of bone growth and maintenance of bone health
EP2135517A1 (en) * 2001-12-11 2009-12-23 Société des Produits Nestlé S.A. Composition for promotion of bone growth and maintenance of bone health
EP2263480A1 (en) * 2001-12-11 2010-12-22 Société des Produits Nestlé S.A. Composition for promotion of bone growth and maintenance of bone health, comprising Mentha extracts
EP2272382A1 (en) * 2001-12-11 2011-01-12 Société des Produits Nestlé S.A. Composition for promotion of bone growth and maintenance of bone health, comprising soybean or soybean extracts
EP2286675A1 (en) * 2001-12-11 2011-02-23 Société des Produits Nestlé S.A. Composition for promotion of bone growth and maintenance of bone health
CN103655959A (en) * 2013-11-21 2014-03-26 黄萍 Externally applied traditional Chinese medicine for treating calcaneodynia
CN104474209A (en) * 2014-12-02 2015-04-01 青岛祥翔生物医药科技有限公司 Traditional Chinese medicine for treating qi-deficiency and blood-deficiency type heel pain

Also Published As

Publication number Publication date
CN1101202C (en) 2003-02-12

Similar Documents

Publication Publication Date Title
CN100350951C (en) External-applied medicine for treating burn, valnus and local tumor inflammation
CN1883534A (en) Medicine for treating orthopaedics disease and preparation method thereof
CN1907410A (en) Chinese traditional medicine preparation for treating bone fracture and traumatic injury
CN101007040B (en) External applied medicine for treating bone fractures
CN1074676C (en) Medicine for treating rheumatic arthritis and hyperosteogeny and preparing process thereof
CN1406594A (en) Oral Chinese medicine for osteoarthritis
CN1101202C (en) Compound Chinese medicine preparation for treating hyperosteogeny
CN1478525A (en) Medicated wine for treating traumatic injury
CN1284580C (en) Bone Activating stasis transforming capsule
CN1846756A (en) Amber bolus
CN1651014A (en) Chinese medicinal preparation for treating rheumatic and homologus rheumatic artbritis
CN101979036A (en) Medicinal liquor for treating rheumatic arthritis
CN1141955C (en) Bi-syndrome treating Chinese medicine preparation
CN1081047C (en) Medicinal liquor for treating rheumatism and atrophic arthritis
CN1136864C (en) Chinese medicine for treating mastoproliferation
CN1279958A (en) Medicine for curing osteomyelitis and its preparing method
CN1267139C (en) Medicinal ointment for bone injury
CN1253179C (en) Drug for treating ischemic necrosis of femoral head
CN1112191C (en) Medicine for treating rheumatic arthritis and hyperosteogeny and its preparing process
CN1189186C (en) Antiphlogistic and analgesic ointment for treating rheumatism and trauma
CN101690750B (en) External medicine for curing hyperosteogeny
CN1194729C (en) External medicine for treating hemorrhoids
CN1127978C (en) Hyperosteogeny treating medicine
CN1164324C (en) Chiese medicine preparation for treating parenchyma pain
CN100335082C (en) Medicine for treating rheumarthritis

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20030212

Termination date: 20130222